Mobile

A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA...

Mise à jour : Il y a 5 ans
Référence : EUCTR2004-002466-38

A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%. 52 week extension to a multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the efficacy of LAF237 in patients with type 2 diabetes with HbA1c 9- 11% by testing the hypothesis that the HbA1c reduction with LAF237 50 mg BID is superior to that with LAF 237 50 mg OD after 12 weeks of treatment.

Critère d'inclusion

  • Diabetes Mellitus

Liens